Phase I, randomized, placebo controlled, double blind, single dose-escalating study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous IQNLF in healthy subjects.

Trial Profile

Phase I, randomized, placebo controlled, double blind, single dose-escalating study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous IQNLF in healthy subjects.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2011

At a glance

  • Drugs IQNLF; IQNLF/IQNPA
  • Indications Anthrax
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Apr 2011 IQ Therapeutics completes dosing of 36 volunteers, according to a company media release.
    • 26 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to information in an IQ Therapeutics media release.
    • 28 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top